# Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

> **NCT05658510** · PHASE3 · COMPLETED · sponsor: **BioXcel Therapeutics Inc** · enrollment: 452 (actual)

## Conditions studied

- Agitation,Psychomotor
- Bipolar I Disorder
- Bipolar II Disorder
- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorders

## Interventions

- **DRUG:** BXCL501
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05658510
- **Lead sponsor:** BioXcel Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-21
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05658510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05658510, "Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT05658510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*